» Authors » Marilyn Huckans

Marilyn Huckans

Explore the profile of Marilyn Huckans including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 36
Citations 672
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Clark J, Mahmood Z, Jak A, Huckans M, ONeil M, Roost M, et al.
J Head Trauma Rehabil . 2022 Nov; 37(6):E488-E495. PMID: 36345556
Objective: To examine the relationship between neuropsychological functioning and performance-based functional capacity in veterans with a history of mild traumatic brain injury (mTBI), as well as the moderating effects of...
2.
Huckans M, Boyd S, Moncrief G, Hantke N, Winters B, Shirley K, et al.
J Clin Exp Neuropsychol . 2021 Oct; 43(6):599-610. PMID: 34612792
Objective: To evaluate whether cognitive performance in adults with active methamphetamine use (MA-ACT) differs from cognitive performance in adults in remission from MA use disorder (MA-REM) and adults without a...
3.
ONeil M, Cameron D, Shirley K, Sano E, Twamley E, Williams R, et al.
J Head Trauma Rehabil . 2021 Mar; 36(6):429-436. PMID: 33656484
Objective: To examine associations among compensatory cognitive training (CCT), objective cognitive functioning, and self-reported cognitive symptoms. We examined whether change in objective cognitive functioning associated with participation in CCT at...
4.
Sandau U, Duggan E, Shi X, Smith S, Huckans M, Schutzer W, et al.
J Extracell Vesicles . 2021 Feb; 10(1):e12028. PMID: 33613872
Methamphetamine (MA) is the largest drug threat across the globe, with health effects including neurotoxicity and cardiovascular disease. Recent studies have begun to link microRNAs (miRNAs) to the processes related...
5.
Mahmood Z, Clark J, Jak A, Huckans M, ONeil M, Roost M, et al.
J Head Trauma Rehabil . 2020 Aug; 36(1):20-24. PMID: 32769826
Objective: The purpose of this study was to determine modifiable predictors of intervention adherence in a study of group-based Compensatory Cognitive Training (CCT) for Iraq/Afghanistan War veterans with a history...
6.
Loftis J, Navis T, Taylor J, Hudson R, Person U, Lattal K, et al.
Eur J Pharmacol . 2020 May; 880:173175. PMID: 32416183
There are no medications that target the neurotoxic effects or reduce the use of methamphetamine. Recombinant T-cell receptor ligand (RTL) 1000 [a partial major histocompatibility complex (pMHC) class II construct...
7.
Loftis J, Lasarev M, Shi X, Lapidus J, Janowsky A, Hoffman W, et al.
PLoS One . 2019 Oct; 14(10):e0220270. PMID: 31600226
Background: Methamphetamine (MA) is a potent agonist at the trace amine-associated receptor 1 (TAAR1). This study evaluated a common variant (CV) in the human TAAR1 gene, synonymous single nucleotide polymorphism...
8.
Kohno M, Link J, Dennis L, McCready H, Huckans M, Hoffman W, et al.
Pharmacol Biochem Behav . 2019 Jan; 179:34-42. PMID: 30695700
Addiction is a worldwide public health problem and this article reviews scientific advances in identifying the role of neuroinflammation in the genesis, maintenance, and treatment of substance use disorders. With...
9.
McCready H, Kohno M, Kolessar M, Dennis L, Kriz D, Luber H, et al.
J Neurovirol . 2018 Oct; 24(6):738-751. PMID: 30298201
Hepatitis C virus-infected (HCV+) adults evidence increased rates of psychiatric and cognitive difficulties. This is the first study to use functional magnetic resonance imaging (fMRI) to examine brain activation in...
10.
Kohno M, Loftis J, Huckans M, Dennis L, McCready H, Hoffman W
Neurosci Lett . 2018 Apr; 677:49-54. PMID: 29689344
Methamphetamine (MA) causes an increase in pro-inflammatory cytokines in animal models and in humans. Resulting activation of microglia and neuro-inflammation could, via effects on reward networks, mediate behavioral characteristics of...